Crossmark

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Crossref DOI link: https://doi.org/10.1038/s41375-024-02420-6

Published Online: 2024-09-25

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lenz, Georg https://orcid.org/0000-0002-4728-1693
Tilly, Hervé

Ziepert, Marita

Altmann, Bettina

Herbaux, Charles https://orcid.org/0000-0003-4910-476X
Frontzek, Fabian

Nickelsen, Maike

Lee, Calvin

Hirata, Jamie

Sahin, Deniz

Chohan, Saibah

Batlevi, Connie Lee

Yan, Mark

Morschhauser, Franck

Schmitz, Norbert https://orcid.org/0000-0003-4938-7528
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche Ltd
License Information

Text and Data Mining valid from 2024-09-25

Version of Record valid from 2024-09-25
More Information

Article History

Received: 15 May 2024

Revised: 18 September 2024

Accepted: 19 September 2024

First Online: 25 September 2024

Competing interests

: GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi.

Document is current

Any future updates will be listed below